A股市场板块涨跌幅排行 中国经济网北京1月5日讯 A股三大指数早盘集体上涨，截至午间收盘，上证指数报4011.45点，涨幅 1.07%；深证成指报13777.32点，涨幅1.87%；创业板指报3272.07点，涨幅2.15%。 行业板块方面，保险、医疗器械、医疗服务等板块涨幅居前，机场航运、旅游及酒店、电机等板块跌 幅居前。 (责任编辑：魏京婷) | 序号 | 板块 | 涨跌幅(%)▼ | | 总成交量（万手） | 净流入 (亿元) ▼ | 上涨家数 | 卜跌家数 | | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 保险 | 5.84 | 243.02 | 109.15 | 20.26 | 5 | 0 | | 2 | 医疗器械 | 5.32 | 910.63 | 216.54 | 35.69 | 130 | 3 | | 3 | 医疗服务 | 5.31 | 686.29 | 158.50 | 22.40 | 51 | വ | | র্ব | # # | 3.70 | 1784.37 | 1391.55 | 158.56 | 163 | 7 | | ...

医疗板块开门红！2026年1月5日早盘，医疗板块全线飘红，全市场规模最大医疗ETF（512170）高开高走，盘中涨超4%，今日有望创下近3个月来最 大单日涨幅！实时成交超6.5亿元。 注：根据沪深交易所数据。风险提示：医疗ETF及其联接基金被动跟踪中证医疗指数，该指数基日为2004.12.31，发布于2014.10.31。指数成份股构成 根据该指数编制规则适时调整，其回测历史业绩不预示指数未来表现。文中指数成份股仅作展示，个股描述不作为任何形式的投资建议，也不代表管 理人旗下任何基金的持仓信息和交易动向。基金管理人评估的医疗ETF联接基金的风险等级为R4-中高风险，适宜积极型（C4）及以上的投资者，医疗 ETF的风险等级为R3-中风险，适宜平衡型（C3）及以上的投资者。任何在本文出现的信息（包括但不限于个股、评论、预测、图表、指标、理论、任 何形式的表述等）均只作为参考，投资人须对任何自主决定的投资行为负责。另，本文中的任何观点、分析及预测不构成对阅读者任何形式的投资建 议，亦不对因使用本文内容所引发的直接或间接损失负任何责任。基金管理人管理的其他基金的业绩并不构成基金业绩表现的保证，基金的过往业绩 并不代表 ...

证券时报·数据宝统计，截至今日上午10:28，上证综指4004.00点，收于五日均线之上，涨跌幅0.89%， A股总成交额为13939.72亿元。到目前为止，今日有1799只A股价格突破了五日均线，其中乖离率较大 的个股有倍益康、伟思医疗、诚益通等，乖离率分别为18.85%、15.01%、14.78%；天和防务、利君股 份、中船科技等个股乖离率较小，刚刚站上五日均线。 （文章来源：证券时报网） | 证券代 | 证券简 | 今日涨跌幅 | 今日换手率 | 五日均线 | 最新价 | 乖离率 | | --- | --- | --- | --- | --- | --- | --- | | 码 | 称 | （%） | （%） | （元） | （元） | （%） | | 920199 | 倍益康 | 29.98 | 11.91 | 37.83 | 44.96 | 18.85 | | 688580 | 伟思医 | 20.00 | 6.89 | 50.50 | 58.08 | 15.01 | | | 疗 | | | | | | | 300430 | 诚益通 | 19.98 | 15.71 | 20.09 | 23.06 | ...

政策端也持续加码支持。国家药监局近期在北京召开脑机接口医疗器械工作推进会，明确表示将加快相 关产品的审评审批流程，推动创新器械更快上市应用。 国金证券指出，在医疗器械创新政策密集落地 背景下，脑机接口作为前沿交叉领域，正迎来从科研验证向临床及消费场景拓展的关键窗口期。 （文章来源：每日经济新闻） 医疗器械ETF（562600）大涨4.36%。截止2025年12月30日，医疗器械ETF脑机接口含量达20.91%。 消息面上，行业迎来多重催化。特斯拉CEO埃隆·马斯克近日在社交媒体透露，其旗下脑机接口公司 Neuralink计划于2026年启动脑机接口设备的"大规模生产"。这一表态被市场视为该技术迈向商业化的重 要信号。 与此同时，由OpenAI首席执行官Sam Altman联合创立的脑机接口初创公司Merge Labs宣布将分拆为独 立实体，专注于开发基于超声波的非侵入式脑信号读取技术。该方案无需植入电极，即可实现对大脑活 动的大范围、高精度解读，有望大幅降低技术门槛与临床风险。 早盘脑机接口概念小幅高开，随后震荡上行，截止10点57分，乐普医疗、美好医疗、翔宇医疗、伟思医 疗、迈普医学封板涨停。 ...

华宝中证医疗ETF（512170）基金经理为胡洁。 1月5日，万东医疗涨5.39%，截至发稿，报16.42元/股，成交1.53亿元，换手率1.35%，总市值115.44亿 元。 资料显示，北京万东医疗科技股份有限公司位于北京市朝阳区酒仙桥东路9号院3号楼，成立日期1997年 5月12日，上市日期1997年5月19日，公司主营业务涉及从事影像类医疗器械的研发、制造、销售及影像 诊断服务。主营业务收入构成为：医疗器械销售业务90.72%，医疗服务及其他5.66%，其他(补 充)3.62%。 从万东医疗十大流通股东角度 数据显示，华宝基金旗下1只基金位居万东医疗十大流通股东。华宝中证医疗ETF（512170）三季度减 持209.86万股，持有股数1191.98万股，占流通股的比例为1.7%。根据测算，今日浮盈赚取约1001.26万 元。 华宝中证医疗ETF（512170）成立日期2019年5月20日，最新规模264.04亿。今年以来收益3.89%，同类 排名3822/4189；近一年收益3.89%，同类排名3822/4189；成立以来收益1.8%。 截至发稿，胡洁累计任职时间13年85天，现任基金资产总规模1002 ...

科创板个股中，截至发稿上涨的有506只，下跌的有91只，涨停的有翔宇医疗、伟思医疗、麦澜德等， 跌幅居前的有铂力特、富吉瑞、步科股份等，分别下跌9.17%、7.81%、6.05%。 资金面上，伟思医疗上一交易日主力资金净流入257.84万元，近5日净流入2054.10万元。 1月5日盘中科创板股伟思医疗涨停，截至09:56，股价报58.08元，成交2.79亿元，换手率5.20%，振幅 12.77%。 融资融券数据显示，该股最新（12月31日）两融余额为1.81亿元，其中，融资余额为1.81亿元，较上一 个交易日减少266.96万元，降幅为1.45%；融券余额为9.68万元，较上一个交易日减少20.45万元，降幅 为67.87%。近10日两融余额合计增加635.15万元，增幅为3.63%，其间融资余额增长3.58%，融券余额增 长441.14%。 从机构评级来看，近一个月该股获1家机构买入评级。12月25日西部证券发布的研报给予公司增持评 级。（数据宝） （文章来源：证券时报网） ...

Market Overview - The A-share market opened strongly on January 5, 2026, with the Shanghai Composite Index returning to the 4000-point level, gaining 35.16 points or 0.89% [2][3] - The ChiNext Index rose over 1%, while the Sci-Tech 50 Index saw an increase of 3.22% [3] Sector Performance - The brain-computer interface (BCI) concept stocks surged, with several stocks hitting the daily limit up, including Meihua Medical, Xiangyu Medical, and Aipeng Medical, all achieving a 20% increase [6][10] - Other active sectors included internet, semiconductor, and gaming, while sectors like catering, tourism, aviation, and duty-free experienced fluctuations [2][4] Notable Stocks - Kuaishou saw a significant rise of over 10%, while Bilibili, Lenovo Group, and SMIC also experienced gains [5][6] - In the BCI sector, notable performers included: - Aipeng Medical: 20% increase, market cap of 4.2 billion - Meihua Medical: 20% increase, market cap of 16.41 billion - Xiangyu Medical: 20% increase, market cap of 11.6 billion [7][9] Gaming Sector - The gaming sector experienced a broad rebound, with Sanqi Interactive Entertainment hitting the daily limit up, and other companies like Tom Cat and Kejing Network also seeing significant gains [10][11] - WeChat Mini Games announced a new incentive policy for developers, enhancing support for quality game content starting January 1, 2026, with incentives exceeding 100% for newly launched games [12] Medical Sector - The healthcare sector saw a rise, with Beiyikang hitting a 30% limit up, and other companies like Weisi Medical and Kangtuo Medical also showing strong performance [8][9]

1月5日，奥精医疗涨5.02%，截至发稿，报21.33元/股，成交5260.64万元，换手率1.82%，总市值29.22 亿元。 融通健康产业灵活配置混合A/B（000727）基金经理为万民远。 截至发稿，万民远累计任职时间9年135天，现任基金资产总规模59.57亿元，任职期间最佳基金回报 130.09%， 任职期间最差基金回报-25.38%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 从奥精医疗十大流通股东角度 数据显示，融通基金旗下1只基金位居奥精医疗十大流通股东。融通健康产业灵活配置混合A/B （000727）三季度新进十大流通股东，持有股数240万股，占流通股的比例为1.75%。根据测算，今日 浮盈赚取约244.8万元。 融通健康产业灵活配置混合A/B（000727）成立日期2014年12月25日，最新规模18.16亿。今年以来收益 8.57%，同类排名6064/8155；近一年收益8.57%，同类排名6064/8155；成立以来收益1 ...

Market Overview - The A-share market experienced a strong start in 2026, with the Shanghai Composite Index returning to the 4000-point level, closing at 4004.00, up 0.89% [2][3] - The ChiNext Index rose over 1%, while the STAR 50 Index saw an increase of 3.22% [2][3] - The total trading volume reached 1.15 trillion CNY, with a predicted turnover of 2.60 trillion CNY, an increase of 536.2 billion CNY compared to previous estimates [3] Sector Performance - The brain-computer interface (BCI) concept stocks surged, with several stocks hitting the daily limit up, including Meihua Medical, Xiangyu Medical, and Aipeng Medical, all achieving a 20% increase [8][12] - Other active sectors included internet, semiconductors, and gaming, while the restaurant, tourism, aviation, and duty-free sectors experienced fluctuations and adjustments [3][4] - The healthcare sector also saw gains, with companies like Beiyikang and Weisi Medical achieving significant increases [8][12] Notable Stocks - Kuaishou saw a notable increase of over 10%, while Bilibili, Lenovo Group, and SMIC also experienced gains [5][6] - The stock prices of several BCI-related companies showed substantial growth, with some reaching daily limits [8][12] Policy Changes - The WeChat Mini Games platform announced an upgrade to its in-app purchase incentive policy, effective January 1, 2026, aimed at supporting quality game development [18] - New games launched on the platform will receive dual incentives during their initial and growth phases, with a maximum incentive cap raised to 4 million CNY per game [18] Commodity Market - On January 5, spot silver prices surged, breaking through 76 USD per ounce, with a daily increase of 3.66%, while gold prices returned above 4400 USD [20][22] - The geopolitical risks have heightened the appeal of precious metals as safe-haven assets, with analysts suggesting further upside potential for gold and silver [25]

Core Insights - The first large-scale national alliance procurement for traditional Chinese medicine (TCM) acupuncture supplies took place on December 30, 2025, organized by the Guangxi Medical Insurance Bureau, covering 25 provinces and regions in China [1][2] - The procurement aims to reduce costs for patients while ensuring the quality and availability of medical supplies, focusing on commonly used items like acupuncture needles and cupping devices [1][2] Summary by Sections Procurement Details - The alliance procurement involves over 2.5 billion units of medical supplies, aiming to leverage bulk purchasing to lower prices and cover over 70% of the TCM service consumption market in China [1] - A group bidding mechanism was introduced, dividing companies into two groups: Group A for mainstream products with established clinical use and Group B for high-cost-performance new products, promoting innovation [1] Pricing and Competition - Multiple rules were implemented to ensure a balance where doctors are willing to use the products, patients can afford them, and companies can still profit [2] - The procurement cycle is set for two years, with the possibility of a one-year extension, and the selected results are expected to be implemented in the first half of 2026 [2] Future Implications - This procurement is seen as a significant step in building a China-ASEAN regional pharmaceutical trading platform, exploring new pathways for quality assurance, price reduction, and stable supply [2]